Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.

Heerspink HJL, Soler M, Beernink JM, Jongs N, Cigarran S, Cigarran S, Cruzado JM, Puchades MJ, López-Martínez M, López-Martínez M, Apperloo E, Waanders F and 9 more

Show all authors

Laverman GD, van der Aart-van der Beek A, van Beek AP, Verhave JC, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Górriz JL

Clinical journal of the American Society of Nephrology : CJASN30 Apr 2026Cited by 1 (Europe PMC)

PMID42308057PMCIDPMC13379112DOI10.2215/cjn.0000001051PepBankPUB-42308057

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with CKD and overweight or obesity, semaglutide changed total body weight by -9.1 kg versus placebo after 24 weeks.
In plain wordsIn adults with kidney disease and overweight, semaglutide lowered body weight more than placebo over 24 weeks.
Peptide
Semaglutide
Outcome
DecreaseTotal body weight change
Study
n = 101
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Total body weight change
−9.1 kg
semaglutide vs placebo
Source sentences
Summary
After 24 weeks of treatment, semaglutide compared with placebo changed total body weight, lean body mass, and fat mass by -9.1 (95% confidence interval [CI], -11.0 to -7.2), -2.5 (95% CI, -6.6 to 1.6), and -3.9 (95% CI, -7.8 to 0.0) kg, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805701
02HumanRandomized controlled trialEfficacy outcome
In adults with CKD and overweight or obesity, semaglutide changed lean body mass by -2.5 kg (95% CI -6.6 to 1.6) versus placebo after 24 weeks; the interval includes no change.
In plain wordsIn adults with kidney disease and overweight, lean mass fell 2.5 kg more on semaglutide than placebo, but the result was uncertain.
Peptide
Semaglutide
Outcome
DecreaseLean body mass change
Study
n = 101
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Lean body mass change
−2.5 kg
semaglutide vs placebo
Source sentences
Summary
After 24 weeks of treatment, semaglutide compared with placebo changed total body weight, lean body mass, and fat mass by -9.1 (95% confidence interval [CI], -11.0 to -7.2), -2.5 (95% CI, -6.6 to 1.6), and -3.9 (95% CI, -7.8 to 0.0) kg, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Treatment with semaglutide compared with placebo for 24 weeks reduced lean body mass and fat mass in adults with CKD and overweight or obesity.
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805702
03HumanRandomized controlled trialEfficacy outcome
In adults with CKD and overweight or obesity, semaglutide changed fat mass by -3.9 kg (95% CI -7.8 to 0.0) versus placebo after 24 weeks; the interval reaches zero.
In plain wordsIn adults with kidney disease and overweight, fat mass fell 3.9 kg more on semaglutide than placebo, but the result was borderline.
Peptide
Semaglutide
Outcome
DecreaseFat mass change
Study
n = 101
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Fat mass change
−3.9 kg
semaglutide vs placebo
Source sentences
Summary
After 24 weeks of treatment, semaglutide compared with placebo changed total body weight, lean body mass, and fat mass by -9.1 (95% confidence interval [CI], -11.0 to -7.2), -2.5 (95% CI, -6.6 to 1.6), and -3.9 (95% CI, -7.8 to 0.0) kg, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Treatment with semaglutide compared with placebo for 24 weeks reduced lean body mass and fat mass in adults with CKD and overweight or obesity.
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805703
04HumanRandomized controlled trialMechanism
During semaglutide treatment, changes in body weight, lean mass and fat mass did not correlate with changes in creatinine or cystatin C eGFR or measured GFR.
In plain wordsWeight, lean mass and fat mass changes on semaglutide were not linked to changes in kidney filtration measures.
Peptide
Semaglutide
Outcome
No significant changeCorrelation of body composition change with eGFR and measured GFR
Study
n = 101
Outcome group
Kidney function · Kidney and urinary
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Spearman correlation coefficient
< 0.23
body composition vs eGFR or mGFR
Source sentences
Summary
No correlations were present between changes in total body weight, lean body mass, and fat mass with changes in eGFR (creatinine or cystatin C) or mGFR during semaglutide treatment (all Spearman correlation coefficients <0.23).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805704
05HumanRandomized controlled trialEfficacy outcome
In adults with CKD and overweight or obesity, semaglutide changed extracellular water by -0.9 L versus placebo after 24 weeks.
In plain wordsIn adults with kidney disease and overweight, semaglutide lowered body water outside cells more than placebo over 24 weeks.
Peptide
Semaglutide
Outcome
DecreaseExtracellular water change
Study
n = 101
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Extracellular water change
−0.9 L
semaglutide vs placebo
Source sentences
Summary
Semaglutide compared with placebo changed extracellular water and systolic BP by -0.9 (95% CI, -1.6 to -0.1) L and -6.3 (95% CI, -10.9 to -1.7) mm Hg, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805705
06HumanRandomized controlled trialEfficacy outcome
In adults with CKD and overweight or obesity, semaglutide changed systolic blood pressure by -6.3 mm Hg versus placebo after 24 weeks.
In plain wordsIn adults with kidney disease and overweight, semaglutide lowered systolic blood pressure more than placebo.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 101
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Systolic BP change
−6.3 mm Hg
semaglutide vs placebo
Source sentences
Summary
Semaglutide compared with placebo changed extracellular water and systolic BP by -0.9 (95% CI, -1.6 to -0.1) L and -6.3 (95% CI, -10.9 to -1.7) mm Hg, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805706
07HumanRandomized controlled trialMechanism
During semaglutide treatment, systolic BP changes correlated with extracellular water changes (Spearman correlation 0.40).
In plain wordsOn semaglutide, bigger drops in body water went together with bigger drops in blood pressure.
Peptide
Semaglutide
Outcome
Not applicableCorrelation of systolic BP change with extracellular water change
Study
n = 101
Outcome group
Blood pressure · Cardiovascular
Studied dose
2.4 mg/wk · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Spearman correlation
0.4
systolic BP vs extracellular water
Source sentences
Summary
Systolic BP changes during semaglutide treatment correlated with extracellular water changes (Spearman correlation 0.40; P = 0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes.
Summary · context
Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment.
Report a problemFND-4230805707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT04889183

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

University Medical Center Groningenn = 12514 Mar 2022 to 28 May 2024

Obesity · Albuminuria

Trial page ClinicalTrials.govUpdated 22 Apr 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.